86045-82-1

Basic information

• Product Name: 4-(benzyloxy)-2,3-dihydroinden-1-one
• Synonyms: 4-(benzyloxy)-2,3-dihydroinden-1-one
• CAS NO: 86045-82-1
• Molecular Formula: C₁₆H₁₄O₂
• Molecular Weight: 238.28116
• Mol File: 86045-82-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 416.5±34.0 °C(Predicted)
• Appearance: /
• Density: 1.193±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(benzyloxy)-2,3-dihydroinden-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(benzyloxy)-2,3-dihydroinden-1-one(86045-82-1)
• EPA Substance Registry System: 4-(benzyloxy)-2,3-dihydroinden-1-one(86045-82-1)

Safety Data

• Hazardous Substances Data: 86045-82-1(Hazardous Substances Data)

Upstream product

• 40731-98-4 4-hydroxy-2,3-dihydroindan-1-one 
• 100-44-7 benzyl chloride 
• 119-84-6 C₆H₄(CH₂CH₂C(O)O) 
• 100-39-0 benzyl bromide 

Downstream Products

• 211805-71-9 4-(benzyloxy)-1-indanol 
• 86045-86-5 4-benzyl-2-hydroxyoxyindyl tosylate 
• 86045-85-4 4-benzyloxyindan-2-ol 
• 86045-88-7 2-iodo-4-benzyloxyindan 
• 86045-84-3 7-(benzyloxy)-1H-indene 
• 2059-92-9 7-Indenol 

Relevant articles and documents

Design, synthesis and bioevalucation of novel 2,3-dihydro-1H-inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline

Parkinson's disease (PD) is associated with elevated levels of hMAO-B in the brain, and MAO-B has been recognized a successful target for developing anti-PD drugs. Herein we report rasagiline derivatives as novel potent and selective hMAO-B inhibitors. Th

Indane derivative and synthetic method and medicinal application thereof

The invention discloses an indane derivative and a synthetic method and medicinal application thereof. The structural general formula is as shown in the specification. The indane derivative disclosed by the invention has excellent inhibitory activity and high selectivity on MAO-B.

NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS

Novel tricyclic compounds of Formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.